Colossal Biosciences, a Texas-based biotech start-up, is making strides in its ambitious de-extinction projects, aiming to resurrect the woolly mammoth, Tasmanian tiger, and dodo bird using advanced gene-editing technologies. Funded by $235 million from a range of investors including celebrities and the CIA, the company plans to have its first woolly mammoth calves born by 2028, utilizing Asian elephants as surrogates due to their genetic similarity. The dodo bird and Tasmanian tiger might be revived even sooner due to their shorter gestation periods. The project has sparked debate, with some viewing it as a distraction from pressing climate issues, while others see potential for biodiversity restoration. Colossal's collaboration with the Mauritian Wildlife Foundation aims to reintroduce the dodo to its native environment in Mauritius. Despite skepticism, the company is confident in its timeline and technological capabilities to rewild these species successfully.